ClinicalTrials.gg
Not yet recruitingNCT07568288Updated May 5, 2026

The Effectiveness of High-intensity Laser Therapy After Arthroscopic Shoulder Rotator Cuff Repair.

An interventional study of High intensity laser therapy and Sham laser therapy in Rotator Cuff Tears, sponsored by Istituto Ortopedico Rizzoli. Not yet recruiting at 1 site in Italy. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rotator Cuff Injuries with a site in Italy — 8 open to participants now, 8 under way, none of them phase 3. Rotator Cuff Injuries · Italy.

Planned enrollment
8th of 14
46 · median 49
Started
2026
with 1 other
No phase
14 of 20
5 open now
Registered
20th of 20
by date
Lead sponsor
6 of 20
Istituto Ortopedico Rizzoli

Among the 20 studies in Rotator Cuff Injuries with a site in Italy, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 20th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

8 of the 20 studies in Rotator Cuff Injuries with a site in Italy are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rotator Cuff Injuries with a site in Italy, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the effectiveness of high-intensity laser therapy (HILT) as an adjunct to conventional rehabilitation in patients undergoing arthroscopic rotator cuff repair.

Despite surgical repair, patients frequently experience postoperative pain, limited range of motion, and delayed functional recovery. Conventional physiotherapy represents the standard of care; however, additional strategies may be needed to optimize outcomes. High-intensity laser therapy has been proposed as a non-invasive intervention with potential analgesic and anti-inflammatory effects, but its effectiveness in the postoperative setting remains unclear.

Participants will be randomly allocated to one of two groups: an experimental group receiving HILT in addition to conventional physiotherapy, and a control group receiving sham laser therapy combined with the same rehabilitation program. Both groups will undergo standardized rehabilitation sessions including therapeutic exercise.

The primary outcome is pain intensity, measured using the Visual Analog Scale. Secondary outcomes include shoulder range of motion (active and passive), muscle strength, functional status assessed with the Constant-Murley Score, and patient-reported disability and quality of life measured using the Shoulder Pain and Disability Index and the Quick Disabilities of the Arm, Shoulder and Hand.

Assessments will be conducted at baseline (at the start of rehabilitation), during the intervention period after the fourth (T1), seventh (T2), and tenth (T3) physiotherapy sessions, and at follow-up at 4 months.

03

Conditions studied

  • Rotator Cuff Tears

Keywords

  • Arthroscopic rotator cuff repair
  • Rotator cuff repair
  • laser therapy
  • High intensity laser therapy
  • Rehabilitation
  • Shoulder pain
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Arthroscopic rotator cuff repair of one shoulder for partial or full-thickness tear
  • Willingness to provide written
  • Age between 30 and 70 years
  • Pain intensity greater than 40/100 on the Visual Analog Scale

Exclusion criteria

Exclusion Criteria:

  • Psychiatric disorders
  • Cognitive impairment
  • Rheumatic diseases or Fibromyalgia
  • Vascular diseases
  • Neoplastic diseases
  • Infectious diseases
  • Neurological disorders
  • Hemophilia or bleeding diathesis
  • Use of anticoagulant therapy
  • Presence of a pacemaker
  • History of epileptic seizures
  • Pregnancy or breastfeeding
  • Skin lesions or abrasions at the laser application site
  • Known to laser therapy or photosensitization
  • Use of photosensitizing medications
  • Tattoo in the treatment area
  • injections in the target area within the previous 2-3 weeks
  • Recent trauma or injury
  • Suspected conditions in which deep tissue heating is
  • Use of analgesic or anti-inflammatory medications during the study period
  • Positive status for infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    High level laser therapy group

    High-intensity laser therapy (HILT) will be administered using the HIRO TT device (ASA s.r.l., Italy), based on a solid-state Nd:YAG laser source with near-infrared emission at a wavelength of 1064 nm. The treatment protocol consists of 10 sessions delivered on alternate days. Each session will last 60 minutes and will include 15 minutes of laser therapy followed by 45 minutes of conventional physiotherapy. Laser therapy will be applied to two areas of 10 × 10 cm each, located at the anterolateral and posterior aspects of the shoulder. The treatment will be delivered using a pulsed emission with a frequency of 15 Hz, a total energy of 1000 J, and an energy density of 5 J/cm². The mean power will range between 6 and 10.5 W, with a peak power between 1 and 3 kW, for a total application time of 8 minutes and 30 seconds.

    Device: High intensity laser therapy

  • Sham comparator
    Sham laser therapy group

    The sham laser intervention will be delivered using the same HIRO TT device and identical treatment procedures as the active HILT group. The same anatomical areas (two treatment areas of 10 × 10 cm located at the anterolateral and posterior aspects of the shoulder) will be targeted, with identical session duration and patient positioning. During sham treatment, the device will remain switched on; however, no therapeutic laser emission will be delivered. This approach is intended to ensure participant blinding by replicating the visual and procedural aspects of the active intervention without providing any active therapeutic effect.

    Other: Sham laser therapy

Interventions

  • DeviceHigh intensity laser therapy

    High-intensity laser therapy (HILT) will be administered using the HIRO TT device (ASA s.r.l., Italy), based on a solid-state Nd:YAG laser source with near-infrared emission at a wavelength of 1064 nm. The treatment protocol consists of 10 sessions delivered on alternate days. Each session will last 60 minutes and will include 15 minutes of laser therapy followed by 45 minutes of conventional physiotherapy. Laser therapy will be applied to two areas of 10 × 10 cm each, located at the anterolateral and posterior aspects of the shoulder. The treatment will be delivered using a pulsed emission with a frequency of 15 Hz, a total energy of 1000 J, and an energy density of 5 J/cm². The mean power will range between 6 and 10.5 W, with a peak power between 1 and 3 kW, for a total application time of 8 minutes and 30 seconds.

  • OtherSham laser therapy

    The sham laser intervention will be delivered using the same HIRO TT device and identical treatment procedures as the active HILT group. The same anatomical areas (two treatment areas of 10 × 10 cm located at the anterolateral and posterior aspects of the shoulder) will be targeted, with identical session duration and patient positioning. During sham treatment, the device will remain switched on; however, no therapeutic laser emission will be delivered. This approach is intended to ensure participant blinding by replicating the visual and procedural aspects of the active intervention without providing any active therapeutic effect.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale

    The VAS consists of a 100-mm horizontal line anchored by two descriptors: "no pain" (0 mm) and "worst imaginable pain" (100 mm). Participants will be asked to mark a point on the line corresponding to their perceived level of pain. The score will be determined by measuring the distance in millimeters from the left end of the line to the patient's mark, with higher scores indicating greater pain intensity.

    Time frame: after 3 weeks

Secondary outcomes

  1. Visual Analogue Scale

    The VAS consists of a 100-mm horizontal line anchored by two descriptors: "no pain" (0 mm) and "worst imaginable pain" (100 mm). Participants will be asked to mark a point on the line corresponding to their perceived level of pain. The score will be determined by measuring the distance in millimeters from the left end of the line to the patient's mark, with higher scores indicating greater pain intensity.

    Time frame: Baseline, after 1 week, after 2 weeks, after 4 months follow-up

  2. Passive Range of Motion

    Passive shoulder range of motion (ROM) will be assessed using a digital goniometer following standardized measurement procedures. Movements evaluated will include shoulder flexion, abduction, internal rotation and external rotation at 90° of abduction, and external rotation at 0° of abduction. Measurements will be performed with the patient in the supine position. For each movement, three repetitions will be recorded and the mean value will be used for analysis. Results will be expressed in degrees.

    Time frame: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up

  3. Active Range of Motion

    Active shoulder range of motion (ROM) will be assessed using a digital goniometer following standardized measurement procedures. Movements evaluated will include shoulder flexion, abduction, and external rotation at 0° of abduction. Measurements will be performed with the patient in a standing position. For each movement, three repetitions will be recorded and the mean value will be used for analysis. Results will be expressed in degrees.

    Time frame: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up

  4. Muscle strength: Handheld dynamometer

    Shoulder muscle strength will be assessed using a handheld digital dynamometer following standardized and reproducible testing positions. Isometric strength will be measured for shoulder abduction, internal rotation, and external rotation. Internal and external rotation will be evaluated with the patient in a seated position, with the arm at 0° and 90° of abduction in the scapular plane. Shoulder abduction will be assessed with the arm positioned at 45° of abduction. For each movement, three maximal isometric contractions of 5 seconds will be performed, with 30 seconds of rest between trials. The highest value recorded will be used for analysis. Results will be expressed in kilograms.

    Time frame: after 3 weeks and after 4 months follow-up

  5. Function: Constant-Murley Score

    Shoulder function will be assessed using the Constant-Murley Score (CMS), a composite scale that evaluates pain, activities of daily living, range of motion, and muscle strength. The total score ranges from 0 to 100, with higher scores indicating better shoulder function.

    Time frame: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up

  6. Disability: Shoulder Pain Disability Index

    Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI), a self-administered questionnaire composed of 13 items divided into two subscales assessing pain and disability. The total score ranges from 0 to 100, with higher scores indicating greater pain and functional impairment.

    Time frame: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up

  7. Disability: Quick Disability of the Arm, Shoulder and Hand

    Upper limb disability will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH), a self-administered questionnaire composed of 11 items rated on a Likert scale. The total score ranges from 0 to 100, with higher scores indicating greater disability.

    Time frame: Baseline, after 1 week, after 2 weeks, after 3 weeks, after 4 months follow-up

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2028, 26 months later.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Nov 2028
CompletionEst.
Sep 2029
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07568288
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
May 5, 2026

Study contacts

Lisa Berti, MD
Contact
lisa.berti@ior.it
0516366197

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion